Triclabendazole

Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME) -dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica[1][2][3].

Product Specifications

CAS Number

[68786-66-3]

Product Name Alternative

CGA89317

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bcl-2 Family; Caspase; Parasite; PARP; Pyroptosis

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/triclabendazole.html

Purity

99.36

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CSC1=NC2=CC(OC3=CC=CC(Cl)=C3Cl)=C(Cl)C=C2N1

Molecular Formula

C14H9Cl3N2OS

Molecular Weight

359.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Yan L, et al. Triclabendazole induces pyroptosis by activating caspase-3 to cleave GSDME in breast cancer cells [J]. Frontiers in Pharmacology, 2021, 12: 670081.|[2]Devine C, et al. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole [J]. Veterinary parasitology, 2012, 184 (1) : 37-47.|[3]Borges B S, et al. In vitro anti-Leishmania activity of triclabendazole and its synergic effect with amphotericin B [J]. Frontiers in Cellular and Infection Microbiology, 2023, 12: 1044665.